A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-Mutant Acute Myeloid Leukemia.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Lestaurtinib (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 31 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.